A recent study analyzed the long-term efficacy and safety profile of anti–tumor necrosis factor (anti-TNF) treatment in 15 patients with rhupus, a rare association defined by the coexistence of both systemic lupus erythematosus and rheumatoid arthritis (RA) in the same patient.
A study published in December 2017 analyzed the long-term efficacy and safety profile of anti—tumor necrosis factor (anti-TNF) treatment in 15 patients with rhupus, a rare association defined by the coexistence of both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in the same patient. Authors of the study note that, to date, there have been no previous studies regarding the use of anti-TNF agents in the treatment of rhupus.
Researchers conducted an open-label, single-center pilot study comprising 15 patients diagnosed with rhupus from 2003 to 2012 with a disease activity score for 28 joints (DAS28) over 3.2. Patients were monitored at 3, 6, 12, 24, and 60 months using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and DAS28.
Of the 15 patients included in the study, 12 were treated with etanercept for a median duration of 62.5 months, and 3 patients were given adalimumab for a median of 36 months. At baseline, median DAS28 and SLEDAI were 5.94 and 6, respectively, in the 2 groups. After 3 months of treatment, DAS28 and SLEDAI decreased to 3.7 and 4, respectively. The authors found that the tolerability and safety profile of the anti-TNF agents were acceptable, with a severe infection rate of 3 per 100 patient years, and with no lupus flares occurring during the follow-up.
The researchers concluded that anti-TNF treatment resulted in an improvement of articular symptoms with a significant decrease of DAS28 score. The SLEDAI score decreased after 3 months of therapy, and these numbers were sustained during the follow-up. Notably, this score also declined without taking into account the arthritis component of the SLEDAI, which the authors suggest could mean that anti-TNF agents could improve the non-articular features of lupus.
This small-scale study suggested that anti-TNF treatment has a “favorable efficacy, a decrease in the median dose of glucocorticoids, and an acceptable tolerance profile in patients with rhupus with refractive arthritis,” said the researchers.
Reference
Danion F, Sparsa L, Arnaud L, et al. Long-term efficacy and safety of anti-tumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients. RMD Open. 2017;3:e000555. doi: 10.1136/rmdopen-2017-000555.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.